|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600124176 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-08 14:26:22 |
|
注册时间: Date of Registration: |
2026-05-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
CRT脉搏血氧饱和度临床试验 |
|
Public title: |
Clinical Trial Protocol for Evaluating CRT Pulse Oximetry Accuracy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
CRT脉搏血氧饱和度临床试验 |
|
Scientific title: |
Clinical Trial Protocol for Evaluating CRT Pulse Oximetry Accuracy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
奉光举 |
研究负责人: |
奉光举 |
|
Applicant: |
Feng Guangju |
Study leader: |
Feng Guangju |
|
申请注册联系人电话: Applicant telephone: |
+86 13823635608 |
研究负责人电话:
Study leader's |
+86 13823635608 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fenggjsz@163.com |
研究负责人电子邮件: Study leader's E-mail: |
fenggjsz@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省深圳市南山区桃园路89号 |
研究负责人通讯地址: |
中国广东省深圳市南山区桃园路89号 |
|
Applicant address: |
89 Taoyuan Road, Nanshan District, Shenzhen, Guangdong, China |
Study leader's address: |
89 Taoyuan Road, Nanshan District, Shenzhen, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
深圳市南山区人民医院 |
||
|
Applicant's institution: |
Shenzhen Nanshan People's Hospital |
||
|
研究负责人所在单位: |
深圳市南山区人民医院 |
||
|
Affiliation of the Leader: |
Shenzhen Nanshan People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
I-2026-01-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
深圳市南山区人民医院药物/医疗器械临床试验伦理委员会 |
||
|
Name of the ethic committee: |
Shenzhen Nanshan People's Hospital Ethics Committee for Drug/Medical Device Clinical Trials |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-14 00:00:00 | ||
|
伦理委员会联系人: |
何念晖 |
||
|
Contact Name of the ethic committee: |
He Nianhui |
||
|
伦理委员会联系地址: |
中国广东省深圳市南山区桃园路89号 |
||
|
Contact Address of the ethic committee: |
89 Taoyuan Road, Nanshan District, Shenzhen, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 755 26553111 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
529749195@qq.com |
|
研究实施负责(组长)单位: |
深圳市南山区人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shenzhen Nanshan People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广东省深圳市南山区桃园路89号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
89 Taoyuan Road, Nanshan District, Shenzhen, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
深圳迈瑞生物医疗电子股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
无 |
||||||||||||||||||||||
|
Target disease: |
None |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价BeneVision V200病人监护仪何CRT-2参数模块和CRT血氧传感器(RT16002)的SpO2监测功能在安静状态下和运动状态下的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effectiveness and safety of the SpO? monitoring function of the BeneVision V200 Patient Monitor with the CRT-2 Parameter Module and the CRT Blood Oxygen Sensor (RT16002) under both resting state and motion state. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)受试者为健康成人,男性和女性,年龄18~45岁,必须理解临床试验并自愿参加并签署知情同意书; (2)满足美国麻醉协会ASA分级I级; (3)受试者碳氧血红蛋白 COHb<3%,高铁血红蛋白MetHb<2%,血红蛋白总浓度ctHb>10g/dL; (4)Allen's试验阴性(提示尺动脉供血良好,该侧桡动脉可用于穿刺); |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Healthy adults, male and female, aged 18-45 years, must understand the clinical trial and voluntarily participate in and sign informed consent; (2) Meet the American Society of Anesthesiologists (ASA) grade I; (3) Subjects' hemoglobin COHb<3%, methemoglobin MetHb<2%, hemoglobin ctHb>10g/dL; (4) Allen's test was negative (indicating that the ulnar artery had good blood supply and the radial artery could be used for puncture); |
||||||||||||||||||||||
|
排除标准: |
(1)受试者患有任何系统性疾病或高铁血红蛋白血症; (2)吸烟者或暴露于较高的一氧化碳含量环境中者; (3)妊娠; (4)受试者有外周缺血的症状或病史; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) the subject had any systemic disease or methemoglobinemia; (2) smokers or those exposed to high levels of carbon monoxide; (3) pregnancy; (4) the subjects had symptoms or history of peripheral ischemia; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-03-31 00:00:00至 To 2026-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-08 00:00:00 至 To 2026-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采集记录在CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Collected and recorded in the CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |